Vera Therapeutics Inc. is a biotechnology company engaged in the research and development of transformative therapies aimed at treating immune-mediated diseases. The primary focus of Vera Therapeutics is to address unmet medical needs, particularly in the treatment of conditions such as immunoglobulin A nephropathy (IgAN), a kidney disorder that can lead to irreversible damage and renal failure. The company's lead asset, atacicept, is a novel, biologic therapeutic that targets specific pathways implicated in the pathogenesis of autoimmune diseases. Vera Therapeutics operates at the forefront of the biotechnology sector, a field characterized by rapid innovation and significant impact on healthcare and disease management. By advancing clinical trials and pursuing regulatory approval for their therapies, Vera Therapeutics contributes significantly to the potential revolutionizing of treatment options for patients with chronic conditions. Founded with a commitment to improving patients' lives, Vera Therapeutics plays a crucial role in expanding the biotech landscape, aiming to bring new hope and effective solutions to markets historically underserved by traditional pharmaceutical approaches.
Website2000 Sierra Point Parkway
Brisbane, CA, 94005
United States
Vera Therapeutics (NasdaqGM: VERA) reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy. The company said the study showed prevention of disease progression and stabilization of kidney function alongside a favorable safety profile. Management plans to seek full FDA approval for TRUTAKNA later in 2026 through a supplemental biologics license application. The confirmation of TRUTAKNA's Phase III success sits against a wider backdrop of...
Vera stock reversed course Tuesday despite positive results for its kidney disease treatment, a rival to drugs from Otsuka and Vertex.
Vera Therapeutics, Inc. gets FDA accelerated approval for Trutakna in IgA nephropathy, but competition and pricing risk remain. Click for this VERA update.
Investors talking about VERA also mention
What share of all stock conversation is about VERA?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% 0 | 0% 0 | 0% 0 |
Of the messages about VERA that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 25% -30.56 | 47.64% -2.14 | 65.51% -24 | ||
| Bearish | — | 75% +30.56 | 52.36% +2.14 | 34.49% +24 |
Of the messages about VERA that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 72% | 47.33% | ||
| Technical Analysis | — | 0% | 1.14% | 2.31% | ||
| Analysts | — | 0% | 0.57% | 33.91% | ||
| Earnings | — | 0% | 26.29% | 3.31% | ||
| Macro | — | 0% | 0% | 12.38% | ||
| Controversies | — | 0% | 0% | 0.75% |
Of the messages about VERA, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 0% | 37.5% | 58.82% | 49.71% | ||
| Newcomers | 100% | 62.5% | 41.18% | 50.29% |